Genetic Analysis of Pathways to Parkinson Disease

Overview

Journal Neuron

Publisher Cell Press

Specialty Neurology

Date 2010 Oct 20

PMID 20955928

Citations 143

Authors

John Hardy

Affiliations

Soon will be listed here.

Abstract

In this review I outline the arguments as to whether we should consider Parkinson disease one or more than one entity and discuss genetic findings from Mendelian and whole-genome association analysis in that context. I discuss what the demonstration of disease spread implies for our analysis of the genetic and epidemiologic risk factors for disease and outline the surprising fact that we now have genetically identified on the order of half our risk for developing the disease.

Citing Articles

De novo missense variant in a patient with Parkinson's disease.

Alluqmani M, Alayoubi A, Hashmi J, Basit S Front Genet. 2024; 15:1496683.

PMID: 39568674 PMC: 11576416. DOI: 10.3389/fgene.2024.1496683.

Yang W, Xu S, Zhou M, Chan P Aging (Albany NY). 2024; 16(17):12191-12208.

PMID: 39264583 PMC: 11424590. DOI: 10.18632/aging.205954.

Low expression of PINK1 and PARK2 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Lu X, Yao Y, Ma Y, Zhang X, Peng H, Pei Y World J Surg Oncol. 2023; 21(1):321.

PMID: 37833780 PMC: 10571472. DOI: 10.1186/s12957-023-03206-3.

Applications of multi-omics analysis in human diseases.

Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J MedComm (2020). 2023; 4(4):e315.

PMID: 37533767 PMC: 10390758. DOI: 10.1002/mco2.315.

Early-Onset Parkinson's Disease: Creating the Right Environment for a Genetic Disorder.

Kolicheski A, Turcano P, Tamvaka N, McLean P, Springer W, Savica R J Parkinsons Dis. 2022; 12(8):2353-2367.

PMID: 36502340 PMC: 9837689. DOI: 10.3233/JPD-223380.

References

Park J, Lee S, Lee S, Kim Y, Song S, Kim S . Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006; 441(7097):1157-61. DOI: 10.1038/nature04788. View

McGeer P, Itagaki S, Boyes B, McGeer E . Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988; 38(8):1285-91. DOI: 10.1212/wnl.38.8.1285. View

McGeer E, Klegeris A, McGeer P . Inflammation, the complement system and the diseases of aging. Neurobiol Aging. 2005; 26 Suppl 1:94-7. DOI: 10.1016/j.neurobiolaging.2005.08.008. View

Frost B, Diamond M . Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2009; 11(3):155-9. PMC: 3648341. DOI: 10.1038/nrn2786. View

Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer K, Wolf B . Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2007; 22(5):1327-34. DOI: 10.1096/fj.07-9348com. View

Ross O, Wu Y, Lee M, Funayama M, Chen M, Soto A . Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol. 2008; 64(1):88-92. DOI: 10.1002/ana.21405. View

Hardy J . Lewy bodies in Alzheimer's disease in which the primary lesion is a mutation in the amyloid precursor protein. Neurosci Lett. 1994; 180(2):290-1. DOI: 10.1016/0304-3940(94)90541-x. View

Singleton A, Myers A, Hardy J . The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum Mol Genet. 2004; 13 Spec No 1:R123-6. DOI: 10.1093/hmg/ddh093. View

Saiki M, Baker A, Williams-Gray C, Foltynie T, Goodman R, Taylor C . Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010; 81(8):890-1. DOI: 10.1136/jnnp.2008.162883. View

10.

Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C . Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308(5720):385-9. PMC: 1512523. DOI: 10.1126/science.1109557. View

11.

Hamza T, Zabetian C, Tenesa A, Laederach A, Montimurro J, Yearout D . Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010; 42(9):781-5. PMC: 2930111. DOI: 10.1038/ng.642. View

12.

Ibanez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M . Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain. 2006; 129(Pt 3):686-94. DOI: 10.1093/brain/awl005. View

13.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere M . Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009; 41(10):1088-93. PMC: 2845877. DOI: 10.1038/ng.440. View

14.

Hughes A, Daniel S, Blankson S, Lees A . A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993; 50(2):140-8. DOI: 10.1001/archneur.1993.00540020018011. View

15.

Gilks W, Abou-Sleiman P, Gandhi S, Jain S, Singleton A, Lees A . A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005; 365(9457):415-6. DOI: 10.1016/S0140-6736(05)17830-1. View

16.

Tan E, Peng R, Teo Y, Tan L, Angeles D, Ho P . Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010; 31(5):561-8. DOI: 10.1002/humu.21225. View

17.

Fung H, Evans J, Evans W, Duckworth J, Pittman A, de Silva R . The architecture of the tau haplotype block in different ethnicities. Neurosci Lett. 2005; 377(2):81-4. DOI: 10.1016/j.neulet.2004.11.072. View

18.

Schapira A . Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2007; 7(1):97-109. DOI: 10.1016/S1474-4422(07)70327-7. View

19.

Sidransky E, Nalls M, Aasly J, Aharon-Peretz J, Annesi G, Barbosa E . Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009; 361(17):1651-61. PMC: 2856322. DOI: 10.1056/NEJMoa0901281. View

20.

Cookson M, Bandmann O . Parkinson's disease: insights from pathways. Hum Mol Genet. 2010; 19(R1):R21-7. PMC: 2875048. DOI: 10.1093/hmg/ddq167. View